Crossover, double‐blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy
- 23 February 2007
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 14 (3), 269-275
- https://doi.org/10.1111/j.1468-1331.2006.01594.x
Abstract
In this randomized, double-blind, crossover clinical trial, adult patients treated two migraine attacks: one with almotriptan 12.5 mg and the other with ergotamine 2 mg plus caffeine 200 mg. Treatment with almotriptan was associated with a significantly greater proportion of patients achieving 2-h pain free (20.9% vs. 13.7%; P < 0.05) and 2-h pain relief (57.7% vs. 44.5%; P < 0.01) compared with ergotamine plus caffeine therapy; significant differences were not seen at 1 h. Rates for sustained pain free and sustained pain free plus no adverse events (AEs) also were significantly greater after almotriptan treatment than after the use of ergotamine plus caffeine (P < 0.05). Almotriptan was associated with a significantly lower rate of photophobia at 90 min (P < 0.05), phonophobia at 60, 90, and 120 min (P < 0.05 to <0.01), and nausea and vomiting at 90 and 120 min (P < 0.01) compared with ergotamine plus caffeine. A significantly greater proportion of patients were more satisfied with almotriptan than with ergotamine plus caffeine (P < 0.05). Sixteen patients reported adverse events during almotriptan treatment and 27 patients reported AEs during the ergotamine plus caffeine therapy. Most AEs were mild-to-moderate and did not result in treatment-related discontinuations. In conclusion, almotriptan was associated with significantly greater efficacy for treating migraine compared with ergotamine plus caffeine, was generally well tolerated and was associated with greater rate of treatment satisfaction.This publication has 30 references indexed in Scilit:
- Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraineInternational Journal of Clinical Practice, 2005
- Efficacy and Tolerability of Almotriptan in Controlled Clinical TrialsEuropean Neurology, 2005
- Defining Response in Migraine: Which Endpoints Are Important?European Neurology, 2005
- Consensus Statement: Cardiovascular Safety Profile of Triptans (5‐HT1B/1D Agonists) in the Acute Treatment of MigraineHeadache: The Journal of Head and Face Pain, 2004
- The Burden of Migraine in SpainPharmacoEconomics, 2004
- Safety profile of the triptansExpert Opinion on Drug Safety, 2003
- Tolerability of the TriptansDrug Safety, 2003
- Side Effects of ErgotamineCephalalgia, 1996
- Migraine Symptoms: Results of a Survey of Self‐Reported MigraineursHeadache: The Journal of Head and Face Pain, 1995
- A Randomized, Double-Blind Comparison of Sumatriptan and Cafergot in the Acute Treatment of MigraineEuropean Neurology, 1991